- Home
- SXTC vs VOR Comparison
SXTC vs VOR Comparison
Compare SXTC & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTC
- VOR
- Stock Information
- Founded
- SXTC 2005
- VOR 2015
- Country
- SXTC China
- VOR United States
- Employees
- SXTC N/A
- VOR N/A
- Industry
- SXTC Biotechnology: Pharmaceutical Preparations
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- SXTC Health Care
- VOR Health Care
- Exchange
- SXTC Nasdaq
- VOR Nasdaq
- Market Cap
- SXTC 184.5M
- VOR 207.1M
- IPO Year
- SXTC 2019
- VOR 2021
- Fundamental
- Price
- SXTC $1.35
- VOR $7.45
- Analyst Decision
- SXTC
- VOR Buy
- Analyst Count
- SXTC 0
- VOR 6
- Target Price
- SXTC N/A
- VOR $80.67
- AVG Volume (30 Days)
- SXTC 244.1K
- VOR 1.0M
- Earning Date
- SXTC 01-01-0001
- VOR 11-13-2025
- Dividend Yield
- SXTC N/A
- VOR N/A
- EPS Growth
- SXTC N/A
- VOR N/A
- EPS
- SXTC N/A
- VOR N/A
- Revenue
- SXTC $1,740,907.00
- VOR N/A
- Revenue This Year
- SXTC N/A
- VOR N/A
- Revenue Next Year
- SXTC N/A
- VOR N/A
- P/E Ratio
- SXTC N/A
- VOR N/A
- Revenue Growth
- SXTC N/A
- VOR N/A
- 52 Week Low
- SXTC $0.95
- VOR $2.62
- 52 Week High
- SXTC $7.84
- VOR $65.80
- Technical
- Relative Strength Index (RSI)
- SXTC 47.18
- VOR 21.62
- Support Level
- SXTC $1.32
- VOR $6.50
- Resistance Level
- SXTC $1.65
- VOR $10.50
- Average True Range (ATR)
- SXTC 0.13
- VOR 1.34
- MACD
- SXTC 0.00
- VOR -0.89
- Stochastic Oscillator
- SXTC 12.77
- VOR 6.52
About SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.